Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research report issued to clients and investors on Monday. The brokerage set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of NASDAQ ADXS opened at $0.03 on Monday. The stock has a market capitalization of $1.15 million, a P/E ratio of 0.00 and a beta of 1.62. The stock’s 50 day moving average price is $0.04 and its two-hundred day moving average price is $0.05. Ayala Pharmaceuticals has a 52-week low of $0.00 and a 52-week high of $1.49.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.